Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517566 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT03517566 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 293 participants.
The verdict
NCT03517566, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
Interventions
- DRUG Placebo
- DRUG ZPL389 30mg
- DRUG ZPL389 50mg
- DRUG ZPL389 3mg
- DRUG ZPL389 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2018-11-14 |
| Est. Completion | 2020-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517566
The ClinicalTrials.gov registry entry for NCT03517566 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03517566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03517566 about?
NCT03517566 is a clinical study titled "A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis". This was a randomized, double-blind, placebo-controlled, parallel-group study to assess safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a total study duration up to 24 weeks
What is the current status of trial NCT03517566?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2018-11-14. Estimated completion is 2020-08-06.
What interventions are being tested in trial NCT03517566?
The interventions under investigation include: Placebo (DRUG), ZPL389 30mg (DRUG), ZPL389 50mg (DRUG), ZPL389 3mg (DRUG), ZPL389 10mg (DRUG).
Who is sponsoring clinical trial NCT03517566?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.